REVIVE, RESOLVE, PREVENT, AND PROTECT Trademark

Serial Number: 98263881

REVIVE, RESOLVE, PREVENT, AND PROTECT is a trademark filed by Rejuve Therapeutics, Inc. on November 9, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Trademark Classes

Class 5 - Pharmaceuticals

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Class 42 - Computer & Scientific

Scientific and technological services; industrial analysis and research services

Owner Contact Info

Rejuve Therapeutics, Inc. (5 trademarks)

1801 Main St STE 1300
Houston, TX 77002-8121

Entity Type: 03

Legal Representation

Attorney of Record

Karen Won

641 trademarks filed View all →

Correspondence Address

Karen Won MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO P.C

ONE FINANCIAL CENTER

BOSTON, MA 02111

United States

Trademark Details

Filing Date

November 9, 2023

Registration Date

Not Registered

Published for Opposition

September 17, 2024

Goods & Services

Pharmaceutical and biological preparations for respiratory diseases and disorders; Pharmaceutical and biological preparations for use in pulmonology, immunology, oncology, infectious diseases, and degenerative diseases; Pharmaceutical and biological preparations for preventing, diagnosing, treating and managing COPD, chronic bronchitis, mucus hypersecretion, emphysema, asthma, sleep apnea, pulmonary hypertension, idiopathic pulmonary fibrosis (IPF), and other diseases, disorders, and conditions affecting the lungs and airways; Pharmaceutical and biological preparations for preventing, diagnosing, treating and managing cancer, fibrotic diseases, NASH, Crohn's Disease, osteoarthritis, viral infections, and hepatitis C; Pharmaceutical and biological preparations for improving air flow obstruction, reduce neutrophils and secreted elastase, improve mucociliary clearance, increase lung cell viability, increase alveolar regeneration, reduce smooth muscle proliferation, regulate cartilage destruction, reduce inflammation; Therapeutic agents in the nature of nebulized peptides, monoclonal antibodies, and recombinant protein domains for reversing underlying mechanisms of COPD

Research and development in the fields of pharmaceuticals, biologics, and therapeutic treatments in the fields of pulmonology, immunology, oncology, infectious diseases, and degenerative diseases; Providing medical scientific research information in the fields of pharmaceuticals, biologics, and therapeutic treatments in the fields of pulmonology, immunology, oncology, infectious diseases, and degenerative diseases